CliffBio
biologic

Omnitrope

somatropin

Loss of exclusivityMay 2018projected — 12-year biologic exclusivity estimate
CompanySandoz →See this company's full patent-cliff portfolio

Drug detail

Brand nameOmnitrope
Active ingredientsomatropin
Strength5.8MG
Dosage formFor Injection
RouteSubcutaneous
ModalityBiologic
FDA approvalMay 2006
Marketing statusRx

More from Sandoz

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Omnitrope patent cliff — loss of exclusivity May 2018 | CliffBio